{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T17:00:11Z","timestamp":1793293211841,"version":"4.5.0"},"reference-count":103,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,10,25]],"date-time":"2023-10-25T00:00:00Z","timestamp":1698192000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:p>Standard treatment for acromegaly focuses on the achievement of target absolute levels of growth hormone (GH) and insulin-like growth factor (IGF-I). The appropriateness of these targets when measured using modern assay methods is not well defined. This paper reviews biochemical status assessed using methods available at the time and associated clinical outcomes. GH measurements were shown to provide an indication of changes in tumor size, and failure of GH suppression after glucose stimulation is associated with tumor recurrence. IGF-I levels were more closely associated with changes in symptoms and signs. Reduced GH and IGF-I concentrations were shown to be associated with increased longevity, although the degree of increase has only been analyzed for GH. Lowering of GH and IGF-I has consistently been associated with improved outcomes; however, absolute levels reported in previous studies were based on results from methods and reference ranges that are now obsolete. Applying previously described absolute thresholds as targets (e.g. \u201cnormal\u201d IGF-I level) when using current methods is best applied to those with active acromegaly symptoms who could benefit from further lowering of biochemical markers. In asymptomatic individuals with mild IGF-I or GH elevations, targeting biochemical \u201cnormalization\u201d would result in the need for combination pharmacotherapy in many patients without proven benefit. Measurement of both GH and IGF-I remains an essential component of diagnosis and monitoring the effectiveness of treatment in acromegaly; however, treatment goals based only on previously identified absolute thresholds are not appropriate without taking into account the assay and reference ranges being employed. Treatment goals should be individualized considering biochemical improvement from an untreated baseline, symptoms of disease, risks, burdens and costs of complex treatment regimens, comorbidities, and quality of life.<\/jats:p>","DOI":"10.3389\/fendo.2023.1266339","type":"journal-article","created":{"date-parts":[[2023,10,25]],"date-time":"2023-10-25T07:56:04Z","timestamp":1698220564000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":25,"title":["Interpreting growth hormone and IGF-I results using modern assays and reference ranges for the monitoring of treatment effectiveness in acromegaly"],"prefix":"10.3389","volume":"14","author":[{"given":"David R.","family":"Clemmons","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Bidlingmaier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,10,25]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgz096","article-title":"A consensus on the diagnosis and treatment of acromegaly comorbidities: an update","volume":"105","author":"Giustina","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.20945\/2359-3997000000192","article-title":"Laboratory investigations in the diagnosis and follow-up of GH-related disorders","volume":"63","author":"Schilbach","year":"2019","journal-title":"Arch Endocrinol Metab"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1172\/JCI39375","article-title":"Acromegaly pathogenesis and treatment","volume":"119","author":"Melmed","year":"2009","journal-title":"J Clin Invest"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1210\/er.2002-0022","article-title":"Systemic complications of acromegaly: epidemiology, pathogenesis, and management","volume":"25","author":"Colao","year":"2004","journal-title":"Endocr Rev"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1093\/qjmed\/hcw004","article-title":"Acromegaly","volume":"110","author":"Dineen","year":"2017","journal-title":"QJM"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1023\/b:pitu.0000011174.79946.10","article-title":"Pitfalls in the biochemical assessment of acromegaly","volume":"6","author":"Freda","year":"2003","journal-title":"Pituitary"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-020-01063-x","article-title":"Prognostic factors of biochemical remission after transsphenoidal surgery for acromegaly: a structured review","volume":"23","author":"Agrawal","year":"2020","journal-title":"Pituitary"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.4158\/ep.10.4.362","article-title":"Role of insulin-like growth factor-I in diagnosis and management of acromegaly","volume":"10","author":"Clemmons","year":"2004","journal-title":"Endocr Pract"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/s1096-6374(03)00029-7","article-title":"Current concepts in the biochemical assessment of the patient with acromegaly","volume":"13","author":"Freda","year":"2003","journal-title":"Growth Horm IGF Res"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1056\/nejm197911223012102","article-title":"Evaluation of acromegaly by radioimmunoassay of somatomedin-C","volume":"301","author":"Clemmons","year":"1979","journal-title":"N Engl J Med"},{"key":"B11","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1210\/er.2018-00115","article-title":"Systemic complications of acromegaly and the impact of the current treatment landscape: an update","volume":"40","author":"Gadelha","year":"2019","journal-title":"Endocr Rev"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1210\/jc.83.11.3808","article-title":"Evaluation of disease status with sensitive measures of growth hormone secretion in 60 postoperative patients with acromegaly","volume":"83","author":"Freda","year":"1998","journal-title":"J Clin Endocrinol Metab"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2005-0901","article-title":"Postoperative evaluation of patients with acromegaly: clinical significance and timing of oral glucose tolerance testing and measurement of (free) insulin-like growth factor I, acid-labile subunit, and growth hormone-binding protein levels","volume":"90","author":"Feelders","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-70-5-1375","article-title":"Somatotropin pulse frequency and basal concentrations are increased in acromegaly and are reduced by successful therapy","volume":"70","author":"Hartman","year":"1990","journal-title":"J Clin Endocrinol Metab"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/ncpendmet0244","article-title":"Clinical utility of measurements of insulin-like growth factor I","volume":"2","author":"Clemmons","year":"2006","journal-title":"Nat Clin Pract Endocrinol Metab"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-013-1262-8","article-title":"Treatment paradigms for pituitary adenomas: defining the roles of radiosurgery and radiation therapy","volume":"117","author":"Ding","year":"2014","journal-title":"J Neurooncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1210\/er.2009-0033","article-title":"Mortality in patients with pituitary disease","volume":"31","author":"Sherlock","year":"2010","journal-title":"Endocr Rev"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2003-031584","article-title":"Growth hormone and pituitary radiotherapy, but not serum insulin-like growth factor-I concentrations, predict excess mortality in patients with acromegaly","volume":"89","author":"Ayuk","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2004-1381","article-title":"A nationwide survey of mortality in acromegaly","volume":"90","author":"Kauppinen-M\u00e4kelin","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-12-0084","article-title":"Predictors of morbidity and mortality in acromegaly: an Italian survey","volume":"167","author":"Arosio","year":"2012","journal-title":"Eur J Endocrinol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-016-0783-5","article-title":"Updates in outcomes of stereotactic radiation therapy in acromegaly","volume":"20","author":"Gheorghiu","year":"2017","journal-title":"Pituitary"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1007\/s11154-020-09588-z","article-title":"Multidisciplinary management of acromegaly: a consensus","volume":"21","author":"Giustina","year":"2020","journal-title":"Rev Endocr Metab Disord"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1007\/s11154-007-9060-2","article-title":"Current diagnosis of acromegaly","volume":"9","author":"Cordero","year":"2008","journal-title":"Rev Endocr Metab Disord"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-016-0725-2","article-title":"Challenges in the diagnosis and management of acromegaly: a focus on comorbidities","volume":"19","author":"Abreu","year":"2016","journal-title":"Pituitary"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.jocd.2012.06.002","article-title":"Vertebral fracture assessment in acromegaly","volume":"16","author":"Madeira","year":"2013","journal-title":"J Clin Densitom"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.83.2.4556","article-title":"Cabergoline in the treatment of acromegaly: a study in 64 patients","volume":"83","author":"Abs","year":"1998","journal-title":"J Clin Endocrinol Metab"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1530\/EC-20-0361","article-title":"Risk factors and management of pasireotide-associated hyperglycemia in acromegaly","volume":"9","author":"Gadelha","year":"2020","journal-title":"Endocr Connect"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2013-2480","article-title":"Pasireotide versus octreotide in acromegaly: a head-to-head superiority study","volume":"99","author":"Colao","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1007\/BF03345632","article-title":"Octreotide-LAR vs lanreotide-SR as first-line therapy for acromegaly: a retrospective, comparative, head-to-head study","volume":"31","author":"Auriemma","year":"2008","journal-title":"J Endocrinol Invest"},{"key":"B30","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1007\/s11102-011-0335-y","article-title":"Comparison of octreotide LAR and lanreotide autogel as post-operative medical treatment in acromegaly","volume":"15","author":"Tutuncu","year":"2012","journal-title":"Pituitary"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2265.2000.01134.x","article-title":"Comparison of octreotide acetate LAR and lanreotide SR in patients with acromegaly","volume":"53","author":"Chanson","year":"2000","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(01)06844-1","article-title":"Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist","volume":"358","author":"van der Lely","year":"2001","journal-title":"Lancet"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-18-0616","article-title":"Long-term treatment with pegvisomant: observations from 2090 acromegaly patients in ACROSTUDY","volume":"179","author":"Buchfelder","year":"2018","journal-title":"Eur J Endocrinol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2010-2443","article-title":"Place of cabergoline in acromegaly: a meta-analysis","volume":"96","author":"Sandret","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1038\/nrendo.2009.175","article-title":"Somatostatin analog and pegvisomant combination therapy for acromegaly","volume":"5","author":"Neggers","year":"2009","journal-title":"Nat Rev Endocrinol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2016-1806","article-title":"Growth hormone and insulin signaling in acromegaly: impact of surgery versus somatostatin analog treatment","volume":"101","author":"Dal","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2005-0331","article-title":"Glucose homeostasis and safety in patients with acromegaly converted from long-acting octreotide to pegvisomant","volume":"90","author":"Barkan","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/s1096-6374(02)00083-7","article-title":"Growth hormone receptor antagonist improves insulin resistance in acromegaly","volume":"12","author":"Rose","year":"2002","journal-title":"Growth Horm IGF Res"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2004-2009","article-title":"Relationship between disease-related morbidity and biochemical markers of activity in patients with acromegaly","volume":"90","author":"Puder","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"B40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11102-020-01091-7","article-title":"A Pituitary Society update to acromegaly management guidelines","volume":"24","author":"Fleseriu","year":"2021","journal-title":"Pituitary"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200004203421604","article-title":"Treatment of acromegaly with the growth hormone\u2013receptor antagonist pegvisomant","volume":"342","author":"Trainer","year":"2000","journal-title":"N Engl J Med"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-17-0996","article-title":"Increasing frequency of combination medical therapy in the treatment of acromegaly with the GH receptor antagonist pegvisomant","volume":"178","author":"Strasburger","year":"2018","journal-title":"Eur J Endocrinol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.87.8.8658","article-title":"Acromegaly with apparently normal GH secretion: implications for diagnosis and follow-up","volume":"87","author":"Dimaraki","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"B44","doi-asserted-by":"publisher","first-page":"S97","DOI":"10.1016\/j.ghir.2004.03.022","article-title":"Biochemical markers of acromegaly: GH vs. IGF-I","volume":"14","author":"Barkan","year":"2004","journal-title":"Growth Horm IGF Res"},{"key":"B45","doi-asserted-by":"publisher","first-page":"E10","DOI":"10.3171\/2020.3.FOCUS2080","article-title":"Impact of tumor characteristics and pre- and postoperative hormone levels on hormonal remission following endoscopic transsphenoidal surgery in patients with acromegaly","volume":"48","author":"Cardinal","year":"2020","journal-title":"Neurosurg Focus"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.3171\/2009.7.Jns09438","article-title":"Significance of postoperative fluid diuresis in patients undergoing transsphenoidal surgery for growth hormone-secreting pituitary adenomas","volume":"112","author":"Zada","year":"2010","journal-title":"J Neurosurg"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-007-0036-8","article-title":"Serum IGF-I levels in the diagnosis and monitoring of acromegaly","volume":"10","author":"Brooke","year":"2007","journal-title":"Pituitary"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.83.8.4995","article-title":"Current treatment guidelines for acromegaly","volume":"83","author":"Melmed","year":"1998","journal-title":"J Clin Endocrinol Metab"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2003-031138","article-title":"Biochemical assessment and long-term monitoring in patients with acromegaly: statement from a joint consensus conference of the Growth Hormone Research Society and the Pituitary Society","volume":"89","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"B50","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1111\/j.1365-2265.2007.02996.x","article-title":"Measurement of basal growth hormone (GH) is a useful test of disease activity in treated acromegalic patients","volume":"68","author":"Jayasena","year":"2008","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2007-1451","article-title":"Assessment of the magnitude of growth hormone hypersecretion in active acromegaly: reliability of different sampling models","volume":"93","author":"Bajuk Studen","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"B52","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1111\/j.1365-2265.2008.03461.x","article-title":"Monitoring disease activity using GH and IGF-I in the follow-up of 501 patients with acromegaly","volume":"71","author":"Sherlock","year":"2009","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.2009.03578.x","article-title":"The value of the oral glucose tolerance test, random serum growth hormone and mean growth hormone levels in assessing the postoperative outcome of patients with acromegaly","volume":"71","author":"Karavitaki","year":"2009","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-011-0313-4","article-title":"Biochemical diagnosis and assessment of disease activity in acromegaly: a two-decade experience","volume":"15","author":"Minuto","year":"2012","journal-title":"Pituitary"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2008-1371","article-title":"The utility of oral glucose tolerance testing for diagnosis and assessment of treatment outcomes in 166 patients with acromegaly","volume":"94","author":"Carmichael","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.2006.02584.x","article-title":"Age changes the diagnostic accuracy of mean profile and nadir growth hormone levels after oral glucose in postoperative patients with acromegaly","volume":"65","author":"Colao","year":"2006","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B57","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1530\/EJE-19-0139","article-title":"Determinants of the growth hormone nadir during oral glucose tolerance test in adults","volume":"181","author":"Schilbach","year":"2019","journal-title":"Eur J Endocrinol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2013-3059","article-title":"Reference intervals for insulin-like growth factor-1 (IGF-I) from birth to senescence: results from a multicenter study using a new automated chemiluminescence IGF-I immunoassay conforming to recent international recommendations","volume":"99","author":"Bidlingmaier","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2016-1257","article-title":"Reference values for IGF-I serum concentrations: comparison of six immunoassays","volume":"101","author":"Chanson","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2007-2454","article-title":"Normal values of circulating insulin-like growth factor-I bioactivity in the healthy population: comparison with five widely used IGF-I immunoassays","volume":"93","author":"Brugts","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaa526","article-title":"Maintenance of acromegaly control in patients switching from injectable somatostatin receptor ligands to oral octreotide","volume":"105","author":"Samson","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2014-4113","article-title":"Safety and efficacy of oral octreotide in acromegaly: results of a multicenter phase III trial","volume":"100","author":"Melmed","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-014-0570-0","article-title":"Octreotide LAR treatment of acromegaly in \"real life\": long-term outcome at a tertiary care center","volume":"18","author":"Espinosa-de-los-Monteros","year":"2015","journal-title":"Pituitary"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2014-2670","article-title":"Successful mortality reduction and control of comorbidities in patients with acromegaly followed at a highly specialized multidisciplinary clinic","volume":"99","author":"Mercado","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-18-0353","article-title":"Efficacy and safety of switching to pasireotide in acromegaly patients controlled with pegvisomant and somatostatin analogues: PAPE extension study","volume":"179","author":"Muhammad","year":"2018","journal-title":"Eur J Endocrinol"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.2005.02233.x","article-title":"Clinical indicators of biochemical remission in acromegaly: does incomplete disease control always mean therapeutic failure","volume":"62","author":"Damjanovic","year":"2005","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.2009.03556.x","article-title":"Monitoring of acromegaly: what should be performed when GH and IGF-1 levels are discrepant","volume":"71","author":"Freda","year":"2009","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaa664","article-title":"Surgical and pharmacological outcomes in acromegaly: real-life data from the Mexican Acromegaly Registry","volume":"105","author":"Mercado","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-020-02227-2","article-title":"Random Gh and Igf-I levels after transsphenoidal surgery for acromegaly: relation with long-term remission","volume":"68","author":"Cunha","year":"2020","journal-title":"Endocrine"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.2006.02430.x","article-title":"Biochemical evaluation of disease activity after pituitary surgery in acromegaly: a critical analysis of patients who spontaneously change disease status","volume":"64","author":"Espinosa-de-Los-Monteros","year":"2006","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2007-2104","article-title":"Divergence between growth hormone and insulin-like growth factor-I concentrations in the follow-up of acromegaly","volume":"93","author":"Alexopoulou","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2019.00736","article-title":"Preoperative fasting C-peptide acts as a promising predictor of improved glucose tolerance in patients with acromegaly after transsphenoidal surgery: a retrospective study of 64 cases from a large pituitary center in China","volume":"10","author":"Wang","year":"2019","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.86.4.7398","article-title":"Predictors of the outcome of surgical treatment in acromegaly and the value of the mean growth hormone day curve in assessing postoperative disease activity","volume":"86","author":"Kaltsas","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1111\/cen.13129","article-title":"The ongoing challenge of discrepant growth hormone and insulin-like growth factor I results in the evaluation of treated acromegalic patients: a systematic review and meta-analysis","volume":"85","author":"Kanakis","year":"2016","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B75","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1007\/s11102-014-0556-y","article-title":"Discordance between growth hormone and insulin-like growth factor-1 after pituitary surgery for acromegaly: a stepwise approach and management","volume":"18","author":"Zeinalizadeh","year":"2015","journal-title":"Pituitary"},{"key":"B76","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s11102-017-0792-z","article-title":"Biochemical investigations in diagnosis and follow up of acromegaly","volume":"20","author":"Schilbach","year":"2017","journal-title":"Pituitary"},{"key":"B77","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1210\/jcem-67-1-69","article-title":"Plasma insulin-like growth factor-I\/somatomedin-C in acromegaly: correlation with the degree of growth hormone hypersecretion","volume":"67","author":"Barkan","year":"1988","journal-title":"J Clin Endocrinol Metab"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1530\/eje.0.1500481","article-title":"Raloxifene decreases serum IGF-I in male patients with active acromegaly","volume":"150","author":"Dimaraki","year":"2004","journal-title":"Eur J Endocrinol"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1016\/j.ghir.2008.02.001","article-title":"Prevalence of discordant GH and IGF-I levels in acromegalics at diagnosis, after surgical treatment and during treatment with octreotide LAR","volume":"18","author":"Machado","year":"2008","journal-title":"Growth Horm IGF Res"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1007\/BF03345170","article-title":"Molecular heterogeneity of human GH: from basic research to clinical implications","volume":"26","author":"Boguszewski","year":"2003","journal-title":"J Endocrinol Invest"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1373\/clinchem.2012.188128","article-title":"Automated 22-kD growth hormone\u2013specific assay without interference from Pegvisomant","volume":"58","author":"Manolopoulou","year":"2012","journal-title":"Clin Chem"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-020-02387-1","article-title":"Discordant biological parameters of remission in acromegaly do not increase the risk of hypertension or diabetes: a study with the Liege Acromegaly Survey database","volume":"70","author":"Amodru","year":"2020","journal-title":"Endocrine"},{"key":"B83","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1055\/s-0035-1569277","article-title":"Evolution of glucose tolerance after treatment of acromegaly: a study in 57 patients","volume":"48","author":"Jonas","year":"2016","journal-title":"Horm Metab Res"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2007-2084","article-title":"Growth hormone response during oral glucose tolerance test: the impact of assay method on the estimation of reference values in patients with acromegaly and in healthy controls, and the role of gender, age, and body mass index","volume":"93","author":"Arafat","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2008-1420","article-title":"Medical therapy in patients with acromegaly: predictors of response and comparison of efficacy of dopamine agonists and somatostatin analogues","volume":"94","author":"Sherlock","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"B86","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1530\/EJE-17-0546","article-title":"Targeting either GH or IGF-I during somatostatin analogue treatment in patients with acromegaly: a randomized multicentre study","volume":"178","author":"Dal","year":"2018","journal-title":"Eur J Endocrinol"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2003-030915","article-title":"Long-term biochemical status and disease-related morbidity in 53 postoperative patients with acromegaly","volume":"89","author":"Serri","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"B88","doi-asserted-by":"publisher","first-page":"e14265","DOI":"10.7759\/cureus.14265","article-title":"Mortality in acromegalic patients: etiology, trends, and risk factors","volume":"13","author":"Alhawyan","year":"2021","journal-title":"Cureus"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1038\/s41574-018-0058-5","article-title":"A consensus statement on acromegaly therapeutic outcomes","volume":"14","author":"Melmed","year":"2018","journal-title":"Nat Rev Endocrinol"},{"key":"B90","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1111\/j.1365-2265.2007.02836.x","article-title":"Variation in GH and IGF-I assays limits the applicability of international consensus criteria to local practice","volume":"67","author":"Pokrajac","year":"2007","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2013-2450","article-title":"A paradigm shift in the monitoring of patients with acromegaly: last available growth hormone may overestimate risk","volume":"99","author":"Sherlock","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.83.10.5222","article-title":"Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly","volume":"83","author":"Swearingen","year":"1998","journal-title":"J Clin Endocrinol Metab"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-13-0166","article-title":"Comparison of the effects of primary somatostatin analogue therapy and pituitary adenomectomy on survival in patients with acromegaly: a retrospective cohort study","volume":"169","author":"Bogazzi","year":"2013","journal-title":"Eur J Endocrinol"},{"key":"B94","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1530\/EJE-08-0267","article-title":"A meta-analysis of the effect of lowering serum levels of GH and IGF-I on mortality in acromegaly","volume":"159","author":"Holdaway","year":"2008","journal-title":"Eur J Endocrinol"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1373\/clinchem.2013.205070","article-title":"Failure of current laboratory protocols to detect lot-to-lot reagent differences: findings and possible solutions","volume":"59","author":"Algeciras-Schimnich","year":"2013","journal-title":"Clin Chem"},{"key":"B96","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1159\/000071871","article-title":"Serum insulin-like growth factor I reference values for an automated chemiluminescence immunoassay system: results from a multicenter study","volume":"60","author":"Brabant","year":"2003","journal-title":"Horm Res"},{"key":"B97","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1530\/EJE-18-0255","article-title":"Mortality in acromegaly decreased in the last decade: a systematic review and meta-analysis","volume":"179","author":"Bolfi","year":"2018","journal-title":"Eur J Endocrinol"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-19-0509","article-title":"Mortality in acromegaly decreased in the last decade: a systematic review and meta-analysis","volume":"181","author":"Bolfi","year":"2019","journal-title":"Eur J Endocrinol"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1530\/eje.0.1510439","article-title":"Epidemiology, clinical characteristics, outcome, morbidity and mortality in acromegaly based on the Spanish Acromegaly Registry (Registro Espa\u00f1ol de Acromegalia, REA)","volume":"151","author":"Mestr\u00f3n","year":"2004","journal-title":"Eur J Endocrinol"},{"key":"B100","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1159\/000375163","article-title":"Treatment factors that influence mortality in acromegaly","volume":"103","author":"McCabe","year":"2016","journal-title":"Neuroendocrinology"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2007-1191","article-title":"Mortality in acromegaly: a metaanalysis","volume":"93","author":"Dekkers","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199810083391508","article-title":"Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Normal reference laboratory values","volume":"339","author":"Kratz","year":"1998","journal-title":"N Engl J Med"},{"key":"B103","unstructured":"AIM Laboratory Test Reference Ranges"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2023.1266339\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,3]],"date-time":"2023-11-03T06:58:38Z","timestamp":1698994718000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2023.1266339\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,25]]},"references-count":103,"alternative-id":["10.3389\/fendo.2023.1266339"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2023.1266339","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,25]]},"article-number":"1266339"}}